Last updated: 5 Nov 2026

ACE
agency for
care effectiveness

Expert Group Composition

The Agency for Care Effectiveness (ACE) acknowledges with appreciation the Expert Group for their professional guidance and technical expertise in the development of the 2026 ACE Clinical Recommendations (ACRs) "Managing Hereditary Breast and Ovarian Cancer (HBOC) Syndrome: genetic testing and risk-reducing interventions". Their contributions have been essential in ensuring the accuracy, comprehensiveness, and practical applicability of these recommendations in the ACRs.

The composition of the Expert Group is detailed below:

Name	Position	Affiliation	Specialty	Role in EG
Prof William Hwang	Senior Consultant, Department of Haematology	National Cancer Centre Singapore	Medical Oncology	Co-chair
Dr Goh Khean Teik	Group Director, Health Services Group	Ministry of Health, Singapore	-	Co-chair
Dr Chan Ching Wan	Senior Consultant & Breast Surgeon	Solis Breast Care & Surgery	General Surgery (Breast)	Member
Clin Asst Prof Rose Fok Wai Yee	Consultant Family Physician; Consultant, Division of Medical Oncology	National Cancer Centre Singapore	Family Medicine	Member
A/Prof Mikael Hartman	Head & Senior Consultant, Division of General Surgery (Breast Surgery), Department of Surgery; Senior Consultant, Division of Surgical Oncology	National University Cancer Institute Singapore	General Surgery (Breast)	Member
Dr Valerie Heong Yue Ming	Senior Consultant, Division of Medical Oncology	Tan Tock Seng Hospital	Medical Oncology	Member
Dr Lee Yien Sien	Deputy Head & Senior Consultant, Department of Diagnostic Radiology	KK Women's and Children's Hospital	Diagnostic Radiology	Member
Ms Li Shao-Tzu	Principal Genetic Counsellor, Division of Medical Oncology – Cancer Genetics Service	National Cancer Centre Singapore	Genetic Counselling	Member
Dr Joline Lim	Senior Consultant	Curie Oncology	Medical Oncology	Member
Dr Ravichandran Nadarajah	Head & Senior Consultant, Department of Gynaecological	KK Women's and Children's Hospital/ Singapore General Hospital	Gynaecologic Oncology	Member

	Oncology (KK Women's and Children's Hospital); Chief of Gynaecology Oncology (Singapore General Hospital & SingHealth)			
A/Prof Joanne Ngeow	Deputy Head Service Chief & Senior Consultant, Cancer Genetics Services	National Cancer Centre Singapore	Medical Oncology	Member
Ms Ong Pei Yi	Senior Cancer Genetics Counsellor, Department of Haematology-Oncology	National University Cancer Institute Singapore	Genetic Counselling	Member
Adj A/Prof Samuel Ow	Senior Consultant, Department of Haematology-Oncology	National University Cancer Institute Singapore	Medical Oncology	Member
Dr Felicity Jane Pool	Senior Consultant, Department of Diagnostic Imaging	National University Hospital Singapore	Diagnostic Radiology	Member
Clin Assoc Prof Rukshini Puvanendran	Head & Senior Consultant, Family Medicine Service; Co-director, KK Menopause Centre	KK Women's and Children's Hospital	Family Medicine	Member
Clin Asst Prof Sim Yirong	Head & Senior Consultant, Department of Breast Surgery, Division of Surgery and Surgical Oncology	National Cancer Centre Singapore	General Surgery (Breast)	Member
A/Prof Tan Ern Yu	Head of Service & Senior consultant, Breast and Endocrine Surgery	Tan Tock Seng Hospital	General Surgery (Breast)	Member
Ms Tay Li Hui	Nurse Clinician	Tan Tock Seng Hospital	Nursing	Member
Dr Pearl Tong	Senior Consultant, Department of Obstetrics & Gynaecology, Division of Gynaecologic Oncology	National University Cancer Institute Singapore	Gynaecologic Oncology	Member
Dr Wong Chiung Ing	Senior Consultant	Parkway Cancer Centre	Medical Oncology	Member
Dr Wong Wai Loong	Senior Consultant	STO+G Women's Health Specialists, Mount Alvernia Hospital	Gynaecologic Oncology	Member

Last updated: 5 Nov 2026

Declarations of interests

The table summarises the interests declared by the members of the Expert Group. **All potential conflicts of interest of the members have been identified and addressed** during the guideline development period based on ACE's conflict of interest policy.

Name	Type of interest[1]	Description of Interest
Prof William Hwang	-	None declared
Dr Goh Khean Teik	-	None declared
Dr Chan Ching Wan	-	None declared
Clin Asst Prof Rose Fok Wai Yee	Direct Interest	Novartis Shared Care Model Delphi Consensus Steering Committee Advisory Board- Early breast cancer and shared care with primary care
A/Prof Mikael Hartman	-	None declared
Dr Valerie Heong Yue Ming	Direct Interest	AstraZeneca (consultancies, honoraria, sponsored talks); Daiichi Sankyo (consultancies, honoraria); Roche, GSK, Abbvie and MSD (sponsored talks, honoraria); DKSH (conference, honoraria)
Dr Lee Yien Sien	-	None declared
Ms Li Shao-Tzu	-	None declared
Dr Joline Lim	-	None declared
Dr Ravichandran Nadarajah	-	None declared
A/Prof Joanne Ngeow	Direct Interest	AstraZeneca (for patient support in HBOC testing); Illumina (research support for lynch cancer, speaker honorarium); Nalagenetics (IAF-ICP grant for long read sequencing); MSD (speaker honorarium)
Ms Ong Pei Yi	-	None declared
Adj A/Prof Samuel Ow	Direct Interest	AstraZeneca and Pfizer (honoraria, advisory board, speaker); AstraZeneca (travel grant)
Dr Felicity Jane Pool	-	None declared
Clin Assoc Prof Rukshini Puvanendran	-	None declared
Clin Asst Prof Sim Yirong	Direct Interest	Co-chair of organizing committee for National Breast Cancer Awareness Month 2025, sponsored by MSD Pharma, Roche, QST technologies, AstraZeneca, Novartis, Becton Dickinson (ceased in Oct 2025); Bertis Inc. for proof of concept for MASTOCHECK (ceased

[1] Type of interest can be classified under "direct interest" or "indirect interest". Direct interest refers to direct commitment, involvement, investment, relationship or obligation where there may be material benefit gained by the individual that may influence his/her judgement in the issues being considered by the group. Indirect interest refers to indirect commitment, involvement, investment, relationship or obligation that may be perceived to be of a material benefit even when no actual benefit was derived and influence the person's judgment in the issues being considered by the group.

		in Feb 2025); Principal investigator of Mirixies at NCCS for development and validation of blood test to detect breast/other cancers
A/Prof Tan Ern Yu	-	None declared
Ms Tay Li Hui	-	None declared
Dr Pearl Tong	-	None declared
Dr Wong Chiung Ing	-	None declared
Dr Wong Wai Loong	-	None declared